Clinical Trial Update: A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission [Phase 3]

View source ↗

Summary

Phase 3 study evaluating dose de-escalation of filgotinib in ulcerative colitis patients in remission was terminated, with results posted on 2024-10-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Filgotinib (filgotinib)

Snippet

Sponsor: Galapagos NV | Conditions: Ulcerative Colitis | Phase 3 | Status: TERMINATED | Results posted: 2024-10-04